These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31252)

  • 21. [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
    Klugmann HJ; Giehler B; Lohmann D; Schiedewitz W
    Gastroenterol J; 1990; 49(4):160-4. PubMed ID: 1970478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral immune system and ulcerative colitis activity. II. Complement level.
    Hermanowicz A; Sliwiński Z; Nawarska Z; Banaś B
    Arch Immunol Ther Exp (Warsz); 1984; 32(5):509-14. PubMed ID: 6152530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rectal tacrolimus in the treatment of resistant ulcerative proctitis.
    Lawrance IC; Copeland TS
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1214-20. PubMed ID: 18761706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative efficacy of mezakol and sulfasalazine in treating chronic relapsing ulcerative colitis].
    Rogozina VA; Rumiantsev VG
    Eksp Klin Gastroenterol; 2003; (1):58-9, 183. PubMed ID: 12664788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pokeweed mitogen stimulated immunoglobulin production by peripheral blood lymphocytes in vitro: evidence for disordered immunoregulation in patients with ulcerative colitis and Crohn's disease.
    Danis VA; Heatley RV
    Clin Exp Immunol; 1983 Dec; 54(3):739-46. PubMed ID: 6606515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral blood mononuclear cells from patients with inflammatory bowel disease exhibit normal function in the allogeneic and autologous mixed leukocyte reaction and cell-mediated lympholysis.
    MacDermott RP; Bragdon MJ; Thurmond RD
    Gastroenterology; 1984 Mar; 86(3):476-84. PubMed ID: 6229444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cell-mediated and humoral immunity in ulcerative colitis. Acute phase reactants (author's transl)].
    Rodríguez de Lope C; San Miguel Joglar G; de las Heras Castaño G; Pons Romero F
    Med Clin (Barc); 1979 Sep; 73(5):180-2. PubMed ID: 315022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of drug therapy for inflammatory bowel disease.
    Peppercorn MA
    Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ropivacaine gel in active distal ulcerative colitis and proctitis -- a pharmacokinetic and exploratory clinical study.
    Arlander E; Ost A; Stahlberg D; Lofberg R
    Aliment Pharmacol Ther; 1996 Feb; 10(1):73-81. PubMed ID: 8871446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.
    Rijk MC; van Lier HJ; van Tongeren JH
    Am J Gastroenterol; 1992 Apr; 87(4):438-42. PubMed ID: 1348159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
    Cohen RD; Woseth DM; Thisted RA; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis.
    Holt PJ; Davies MG; Saunders KC; Nuki G
    Medicine (Baltimore); 1980 Mar; 59(2):114-33. PubMed ID: 7360040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
    Habal FM; Greenberg GR
    Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical picture and therapy of nonspecific ulcerative proctitis (author's transl)].
    Schütze K; Hentschel E
    Wien Med Wochenschr; 1982 Feb; 132(4):91-3. PubMed ID: 6123196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Characteristics of the disorders of the T chain of the immune system in nonspecific ulcerative colitis and their significance in choosing effective therapy].
    Shakhnazarov AA
    Ter Arkh; 1984; 56(2):106-8. PubMed ID: 6608803
    [No Abstract]   [Full Text] [Related]  

  • 36. [Chronic ulcerative colitis and autoimmune hemolytic anemia (author's transl)].
    Vilaseca J; Tor J; Puig Costa M; Ribera A; Martín C; Guardia J
    Med Clin (Barc); 1980 Jul; 75(3):126-8. PubMed ID: 6105235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutical experiments in ulcerative colitis and Crohn's disease.
    Nagy G; Prónay G; Ujszászy L
    Acta Med Hung; 1985; 42(3-4):163-74. PubMed ID: 2869469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vitro effect of corticosteroids on T-lymphocyte subpopulations in patients with ulcerative colitis.
    Nikolopoulou VN; Gogos CA; Zoumbos NC
    Z Gastroenterol; 1990 Feb; 28(2):101-3. PubMed ID: 2138831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy and tolerability of 5-aminosalicylic acid in the short-term treatment of ulcerative rectocolitis during the mild or moderate stage].
    Bresci G; Carrai M; Venturini G; Gambardella L
    Minerva Dietol Gastroenterol; 1990; 36(1):31-3. PubMed ID: 1970855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.